Last reviewed · How we verify
NCT06883565
Tertiary Lymphoid Structures Related Genes Predicting Prognosis in Clear Cell Renal Cell Carcinoma: a Retrospective Cohort Study
trial in Renal Cell Carcinoma (RCC) in 232 participants. Completed in 31 January 2025.
31 January 2025
Quick facts
| Lead sponsor | Ding-Wei Ye |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 232 |
| Start date | 1 June 2024 |
| Primary completion | 31 January 2025 |
| Estimated completion | 31 January 2025 |
| Sites | 1 location across China |
Conditions studied
- Renal Cell Carcinoma (RCC) — all drugs for Renal Cell Carcinoma (RCC) →
Sponsor
Ding-Wei Ye — full company profile →
Who can join
Eligibility, any sex, with Renal Cell Carcinoma (RCC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research was to uncover the prognostic significance of tertiary lymphoid structures related genes from ccRCC patients with respect to clinical characteristics and outcomes. This offers a novel perspective on selecting populations for prostate cancer immunotherapy in future scenarios.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Therapy-induced remodeling of the tumor immune microenvironment: Mechanistic insights and implications for immunotherapy.
Chen D, Wu R, Liu Z, Wei Y, et al · · 2026 · PMID 41813658 · DOI 10.1097/cm9.0000000000004035
Verify or expand the search:
- PubMed search for NCT06883565
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Cell Carcinoma (RCC)
Currently open trials in the same condition.
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
- NCT07197580 — Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC · Phase 3 · recruiting
- NCT07077161 — Cabozantinib Dose Skipping as an Alternative to Dose Reductions · Phase 2 · recruiting
- NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
Other Ding-Wei Ye trials
Trials by the same sponsor.
- NCT06768255 — Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC · Phase 3 · not yet recruiting
- NCT07505615 — A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06883565 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ding-Wei Ye
- Last refreshed: 19 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06883565.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing